Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2006

01-11-2006

Antiangiogenic effect of 2-benzoyl–phenoxy acetamide in EAT cell is mediated by HIF-1α and down regulation of VEGF of in-vivo

Authors: B. T. Prabhakar, Shaukath Ara Khanum, S. Shashikanth, Bharathi P. Salimath

Published in: Investigational New Drugs | Issue 6/2006

Login to get access
Metadata
Title
Antiangiogenic effect of 2-benzoyl–phenoxy acetamide in EAT cell is mediated by HIF-1α and down regulation of VEGF of in-vivo
Authors
B. T. Prabhakar
Shaukath Ara Khanum
S. Shashikanth
Bharathi P. Salimath
Publication date
01-11-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 6/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-6587-0

Other articles of this Issue 6/2006

Investigational New Drugs 6/2006 Go to the issue

Phase II studies

Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

Phase II Studies

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

Phase I Studies

A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies

Preclinical Studies

Studies on reaction of amino acids and triplet thioxanthone derivatives by laser flash photolysis

Phase II Studies

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study

Phase II Studies

Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits